Home Journals Articles Updates About
CN
image
Home Latest Articles
Latest Articles
  • Biomimetic liposomes synergize with high-intensity focused ultrasound to induce ferroptosis in tumors
    Acta Pharmaceutica Sinica B. 2026, 16(5): 3224-3242.
    The efficient targeted delivery and on-demand release of nanomedicines still present significant challenges in tumor therapy. In the present study, we developed a novel strategy of tumor ferroptosis therapy through the synergistic effect of nanomedicines (biomimetic liposomes) and a medical device (high-intensity focused ultrasound, HIFU). It was found that HIFU irradiation induced heightened expressions of CD44 and reactive oxygen species (ROS) in tumor cells by 1.43-fold and 2.64-fold, respectively. This allowed the gambogic acid-loaded, platelet-mimicking liposomes (PLip) to more precisely target the tumor cells through the interaction of CD44 and P-selectin on the PLip and subsequently ROS-responsively release the drug from PLip, thus effectively killing tumor cells. Crucially, gambogic acid also significantly enhanced ROS production, leading to lipid peroxidation and augmented ferroptosis induced by HIFU. In summary, HIFU demonstrates immense potential in synergizing with nanomedicines to combat tumors.
  • Urate transporters: Structural mechanisms and therapeutic opportunities in drug development
    Acta Pharmaceutica Sinica B. 2026, 16(5): 3243-3248.
  • Hypoxia-selective targeting of eEF1A1: A promising therapeutic strategy for triple-negative breast cancer
    Acta Pharmaceutica Sinica B. 2026, 16(5): 3249-3250.
  • Sonic priming and biomimetic synergy: A paradigm shift in solid tumor therapy
    Acta Pharmaceutica Sinica B. 2026, 16(5): 3251-3253.
  • Author correction to “Triterpenoids-templated self-assembly nanosystem for biomimetic delivery of CRISPR/Cas9 based on the synergy of TLR-2 and ICB to enhance HCC immunotherapy” [Acta Pharm Sin B 14 (2024) 3205-3217]
    Acta Pharmaceutica Sinica B. 2026, 16(5): 3254-3255.
  • Editor Profiles: Guest Editors of Special Column on Hot Topic Reviews in Drug (II)
    Acta Pharmaceutica Sinica B. 2026, 16(4): 1801-1801.
  • Editorial of special column of hot topic reviews in drug delivery (II)
    Acta Pharmaceutica Sinica B. 2026, 16(4): 1802-1803.
  • From conceptual design to translational progress: Emerging advances in intelligent microneedles for biomedical applications
    Acta Pharmaceutica Sinica B. 2026, 16(4): 1804-1847.
    Microneedles (MNs), as innovative biomedical devices, are undergoing a transformation from basic transdermal devices to intelligent and multifunctional systems. The advancement of intelligent MNs enhances tissue penetration and adhesion, triggers timely, on-demand and precise spatiotemporal controlled release, achieves sequential drug delivery and in situ monitoring, and enables close-loop theranostics via the integration of flexible electronics, wireless communication, and artificial intelligence. This review not only systematically highlights these cutting-edge breakthroughs, focusing on five major innovative advancements of conceptual design, including mimicking strategies, stimuli-responsive systems, innovative structural designs, living payload, and wearable integration, but also delineates the principal obstacles obstructing the advancement of intelligent MNs. We also emphasize that MN technology is fueling the evolution of next-generation medical paradigms based on its personalized, minimally invasive, and intelligent features through interdisciplinary integration, which is crucial for reshaping the future landscape of disease diagnosis and treatment.
  • Crystal engineering for poorly water-soluble drugs: From design to applications
    Acta Pharmaceutica Sinica B. 2026, 16(4): 1848-1882.
    The limited aqueous solubility of active pharmaceutical ingredients (APIs) remains a major challenge in drug development, severely compromising clinical performance. Crystal engineering has emerged as a powerful and versatile approach to address this issue by rationally designing API crystal structures through precise control of intermolecular interactions, thereby enhancing solubility, dissolution rates, and ultimately bioavailability. This review systematically summarizes recent advances in crystal engineering strategies for poorly water-soluble drugs, including polymorphs, cocrystals, solvates/hydrates, nanocrystals, organic framework solids, solid solutions, liquid crystals, amorphous solids, and salts. Additionally, key challenges in translational applications are discussed, including structure-property relationship, AI-driven computational modeling, in vitro-in vivo correlation establishment, and advanced crystallization techniques. The review aims to provide strategic insights of crystal engineering for overcoming solubility barriers in next-generation drug formulations.
  • Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer
    Acta Pharmaceutica Sinica B. 2026, 16(4): 1883-1913.
    Proteins have emerged as highly promising biomaterials for the design of drug-loaded nanocarriers due to their biocompatibility, biodegradability and reduced immunogenicity. Among them, albumin stands out as the most widely used due to its unique physicochemical and biological properties, high affinity to important cell surface receptors, structural stability, long circulation time and intrinsic binding capacities. This review provides an overview of the advantages and limitations of the main proteins that have been proposed as biomaterials for nanoparticle fabrication, with a specific focus on albumin-based systems. It explores the physicochemical characteristics of these nanosystems, receptor binding affinity and functionalization strategies for both passive and active tumor targeting. The main synthesis methods and functionalization strategies are discussed, highlighting their relevance in cancer therapy. Their clinical relevance is stressed by the US Food and Drug Administration (FDA)-approved formulations and the additional albumin-bound drugs in ongoing trials. Despite promising preclinical data and numerous active targeting approaches reported, clinical translation remains limited. This review provides the necessary information to develop improved strategies and cover the gap between preclinical research and clinical application and outlines future perspectives for enhancing the therapeutic efficacy and specificity of albumin-based drug delivery nanosystems in oncology.
Submission
Peer Review
Staff Login
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House